Israeli founded Cleveland Diagnostics (CDX) is developing a technology and test kit that can eradicate inconclusive prostate-specific antigen (PSA) tests. CDX says it will save the $4000 cost per negative biopsy, currently necessary in 70% of current testing.
http://www.timesofisrael.com/new-prostate-cancer-test-strives-to-slash-biopsies/
Pingback: The next generation in cancer diagnostics - Israel Active